Daily Stock List
First Choice Healthcare Solutions, Inc. (FCHS)
Marketbeat, Greenbackers, 007 Stock Chat, PennyStockSpy, StocksImpossible, TheMicrocapNews, First Penny Picks, and OTCBB Journal reported earlier on First Choice Healthcare Solutions, Inc. (FCHS), and today we report on the Company, here at the QualityStocks Daily Newsletter.
First Choice Healthcare Solutions, Inc. (FCHS) involves in owning and operating multi-specialty (non-physician-owned) medical centers of excellence across the southeastern United States. The Company is one of the nation's only non-physician-owned, publicly traded healthcare services enterprises focused on the delivery of total musculoskeletal solutions with an emphasis on Orthopaedic and Spine care. Listed on the OTCQB, FCHS is based in Melbourne, Florida.
The Company’s commitment is to deliver clinically superior, patient-centric care. Its flagship integrated platform presently administers over 100,000 patient visits annually and comprises First Choice Medical Group, The B.A.C.K. Center, and Crane Creek Surgery Center.
FCHS medical centers of excellence focus on treating patients in diverse specialties. These include Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management and related diagnostic and ancillary services. First Choice Medical Group (Melbourne, Florida) is FCHS’s flagship multi-specialty medical center of excellence. First Choice Medical Group specializes in the delivery of musculoskeletal medicine and rehabilitative care with many quality-focused goals centered on enriching its patients’ care experience.
FCHS has expanded its portfolio of Medical Centers of Excellence in the Florida Space Coast area, with its Brevard Orthopaedic Spine & Pain Clinic, Inc., dba The B.A.C.K. Center. The B.A.C.K. Center is a foremost, advanced orthopaedic spine and pain practice in Brevard County, Florida. It concentrates on Spinal Care & Surgery; Non-Operative Spine Procedures; Chiropractic Services; Osteoporosis Care; Acupuncture; and Interventional Pain Management.
FCHS’s Crane Creek Surgery Center is an AAAHC accredited facility. Its commitment is to deliver premier, ambulatory surgical care in a convenient, comfortable outpatient environment. The 18,000-plus sq. ft. facility is in Melbourne, Florida within the Crane Creek Medical Center building. This building is also home to The B.A.C.K. Center.
Last month, First Choice Healthcare Solutions announced that Mr. James B. Billys, M.D. joined the medical staff at The B.A.C.K. Center (TBC). Dr. Billys will specialize in minimally invasive spine surgery. He has served as the Principal Investigator or sub-investigator of many pioneering clinical studies led by the Foundation for Orthopaedic Research and Education over the past 12 years. Dr. Billys is dual board certified in Orthopaedic Surgery and Surgery of the Hand by the American Board of Orthopaedic Surgery, and fellowship trained in Spine Surgery at Stanford University and in Hand and Microvascular Reconstructive Surgery at Davies Medical Center in San Francisco.
This week, First Choice Healthcare Solutions announced its 2016 financial results for the 12 months ended December 31, 2016. Key 2016 financial highlights versus 2015 include Total Revenues increasing 51 percent to $29,464,082 from $19,517,664. Net Patient Service Revenue grew 52 percent to $27,053,190 from $17,770,697. Net Income Attributable to First Choice totaled $9,174,383, or $0.38 earnings per share, versus a net loss of $3,421,841, or $0.17 loss per share.
First Choice Healthcare Solutions, Inc. (FCHS), closed Monday's trading session at $1.60, up 1.27%, on 56,820 volume with 52 trades. The average volume for the last 60 days is 25,365 and the stock's 52-week low/high is $0.74/$1.75.
Lexaria Bioscience Corp. (LXRP)
SmallCap Network, Wealth Insider Alert, CFN Media Group, StreetAuthority Daily, MassiveStockProfits, AllPennyStocks, Stockgoodies, WealthMakers, BUYINS.NET, Cannabis Financial Network News, Stock Commander, and Wall Street Resources reported earlier on Lexaria Bioscience Corp. (LXRP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Lexaria Bioscience Corp. is a food sciences company with its corporate headquarters in Kelowna, British Columbia. Its focus is on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies. The Company previously went by the name Lexaria Corp. It changed its name to Lexaria Bioscience Corp. in April of last year. In addition, Lexaria Bioscience, via its subsidiary, PoViva Tea LLC, produces and sells hemp oil enriched teas under the ViPova brand name in the U.S. Lexaria Bioscience’s shares trade on the OTCQB.
The Company’s technology enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine, and other molecules than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria’s emphasis is on the delivery of hemp oil compounds procured from legal, agricultural hemp seed oil, by way of gourmet foods products established upon its proprietary infusion technologies.
The Company’s ViPova™ Tea is made with a rich, smooth organic black tea from China’s renowned Yunnan Province and first-rate rich hemp oil derived from the highest quality agricultural hemp cultivars. PoViva Tea LLC employs its own patent-pending process to infuse the valuable hemp oil ingredients inside lipids. This allows a more efficient and comforting delivery to one’s body.
Recipe development for Lexaria Bioscience’s new Lexaria Energy bar is taking place. The Company’s focus is an Energy Bar high in protein, but balanced with fiber and the right amount of carbohydrates. First-generation prototypes have been produced. In addition, the Company is part of a joint venture (JV) that has filed an application in Canada to be permitted to grow and sell medical marijuana in Canada under the Marihuana for Medical Purposes Regulations (MMPR) legislation.
Lexaria Bioscience and NeutriSci International, Inc. announced in January of this year the successful development and initial trial of the industry’s first zero-sugar cannabinoid/pterostilbene edible tablet employing Neutrisci’s and Lexaria’s proprietary and patented technologies. NeutriSci specializes in the innovation, production and formulation of nutraceutical products.
Lexaria Bioscience, via its wholly-owned Canadian subsidiary, Lexaria Canpharm Corp., signed and entered a master collaborative research agreement with the National Research Council of Canada (NRC) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions. Lexaria believes that results from this scientific collaboration could motivate license adoption of the Company’s patented flavor masking and nutrient delivery enhancement technology.
Last month, Lexaria Bioscience announced the introduction of the TurboCBD™ brand of technologically enhanced, high absorption full spectrum hemp oil capsules. Its TurboCBD™ capsules are specially formulated with premier American Ginseng and Ginkgo Biloba for support of enhanced focus and memory, and reduced stress and fatigue.
Lexaria Bioscience Corp. (LXRP), closed Monday's trading session at $0.54, down 3.40%, on 859,271 volume with 291 trades. The average volume for the last 60 days is 274,827 and the stock's 52-week low/high is $0.0804/$0.699.
Wealth Minerals Ltd. (WMLLF)
We are highlighting Wealth Minerals Ltd. (WMLLF) today, here at the QualityStocks Daily Newsletter.
Wealth Minerals Ltd. is a mineral resource company headquartered in Vancouver, British Columbia. It has interests in Canada, Mexico, Peru and Chile. The Company’s principal focus is the acquisition of Lithium projects in South America. This includes interests in the Maricunga Salar in Chile. So far, Wealth Minerals has positioned itself to develop the Aguas Calientes Norte, Pujsa and Quisquiro Salars in Chile (the Trinity Project), and to work alongside existing producers in the prolific Atacama Salar. Wealth Minerals lists on the OTCQB.
The Company also maintains a portfolio of precious and base metal exploration-stage projects. This portfolio includes the 100 percent Wealth Minerals-owned Coronado property in southern Chihuahua, Mexico that spans 9911 Ha. Additionally, the portfolio includes Yanamina (Peru) and Valsequillo (Mexico). Yanamina is an advanced-stage gold property in the Department of Ancash in north-central Peru. The Valsequillo Silver project is in southern Chihuahua State, Mexico, roughly 40 kilometers southeast of the city of Hidalgo Del Parral.
Wealth Minerals announced in November 2016 that its wholly-owned Chilean subsidiary (Wealth Chile) entered into a formal option agreement with Atacama Lithium SpA, where it has been given the exclusive right and option to acquire a 100 percent royalty-free interest in 144 exploration concessions referred to as the Proyecto Atacama Lithium project positioned in the Atacama Salar in Region II of Antofagasta, northern Chile.
Wealth Minerals’ Wealth Chile entered into a Letter of Intent (LOI) dated December 12, 2016 with arm’s length vendors. As a result, it was given the exclusive right and option to acquire a 100 percent royalty-free interest in the mining concessions referred to as the Laguna Verde project.
The Project consists of 23 Concessions for a total of 2,438 hectares. It is in Region III, northern Chile, 193 km east of the regional capital city of Copiapo, adjacent to Highway 60 and 15 km west of the border with Argentina. Last week, Wealth Minerals reported that it initiated an extensive lake-brine sampling and project evaluation program at the Laguna Verde Lithium Project in Chile.
In March, Wealth Minerals reported that, in connection with the earlier announced grant to the Company of an option to acquire a 100 percent royalty-free interest in and to the Proyecto Atacama Lithium (the Project), it filed on SEDAR a National Instrument 43-101 (NI 43-101) technical report titled “NI 43-101 Technical Report on the Atacama Lithium Project El Loa Province Region II Republic of Chile” dated March 10, 2017.
Wealth Minerals’ Chief Executive Officer, Mr. Henk van Alphen, stated, “The Report filed today is an important development for Wealth and the Project. The Report provides an independent assessment of Wealth’s lithium brine exploration model and comprehensive recommendations for upcoming exploration and Project evaluation.”
Wealth Minerals Ltd. (WMLLF), closed Monday's trading session at $1.13, down 3.09%, on 30,935 volume with 44 trades. The average volume for the last 60 days is 69,321 and the stock's 52-week low/high is $0.3292/$1.37.
Pura Naturals, Inc. (PNAT)
OTC Markets, ADVFN, and MarketWatch reported on Pura Naturals, Inc. (PNAT), and we also report on the Company, here at the QualityStocks Daily Newsletter.
Pura Naturals, Inc. is working to deliver a purer clean by way of its leading-edge BeBetter Foam®. The Company is the manufacturer of innovative foam cleaning products for the home. It has its proprietary foam technology that absorbs grease and grime like a magnet. It does so without harsh chemicals and harboring of bacteria found within traditional household cleaning products and sponges. The Company concentrates on plant-based products made from renewable resources with no petroleum by-products. Pura Naturals is based in Lake Forest, California.
The Company’s household cleaning product delivers an inventive soap infusion. Its foam technology underwent development in response to the Gulf oil spill. The ground-breaking foam absorbs grease while repelling water and inhibiting bacteria growth and odors.
Pura Naturals’ product portfolio includes Health & Beauty products, including facial pads, exfoliating soap-infused body bars, soap-infused sponges, and soap-infused gentle cleansing pads for babies. Kitchen & Household products include sponges, soap-infused sponges, non-scratch scrubbers, and non-scratch scrubbers (soap-infused).
Furthermore, the Company has its Pura Naturals Marine. The specific design of its marine foam is to handle petroleum base contaminations. It is approved for use by the Environmental Protection Agency (EPA).
Pura Naturals Marine products are made in the U.S. to a carbon negative footprint. Its Marine products are reusable and absorb up to 14 times their weight. Marine products include all-purpose sorbent Spill Pads, bilge sorbent Bilge Booms, Spill Bibs (fuel spill prevention), soap-infused personal cleaning bars, and soap-infused galley sponges.
In January 2017, Pura Naturals announced the launch of the Pura Marine division. Pura Marine centers on developing solutions utilizing AirTech Foam technologies and allied products directed towards oil spill prevention and remediation in waterways. Currently, this division is in negotiations with some of the largest marine oil transport companies in the U.S. and is also pursuing business in the trucking and oil sectors.
In February, Pura Naturals announced that manufacturing was taking place on orders from Permatex®, a division of Illinois Tool Works, Inc., for the new Fast Orange®-Infused Grime Magnet. This cleaning product will exploit the power of Pura Naturals’ foam technology infused with the Permatex® proprietary Fast Orange® cleansing gel.
Last month, Pura Naturals announced the appointment of Mr. Daniel Kryger to the role of Vice President of Business Development. Mr. Kryger has a notable background in financial and regulatory compliance. He has expertise in operations management, efficiency improvement, as well as strategic planning. His main responsibilities will be centered on managing Pura Naturals’ strategic relations.
Pura Naturals, Inc. (PNAT), closed Monday's trading session at $1.22, down 3.86%, on 130,075 volume with 131 trades. The average volume for the last 60 days is 502,828 and the stock's 52-week low/high is $0.1486/$3.70.
Northwest Biotherapeutics, Inc. (NWBO)
The Street, Marketbeat, Promotion Stock Secrets, RedChip, Wall Street Corner, BUYINS.NET, INO Market Report, WealthMakers, PureActionStocks, Pennybuster, InvestorPlace, StockPicksNYC, Streetwise Reports, Wealthpire, StreetInsider, OTCPicks, FeedBlitz, AllPennyStocks, SmallCapVoice, BullRally, and CoolPennyStocks reported earlier on Northwest Biotherapeutics, Inc. (NWBO), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.
Northwest Biotherapeutics, Inc. is a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers. In the United States and Europe, the Company’s concentration is on developing personalized immunotherapy products, on a cost-effective basis, designed to treat cancers more effectively than present treatments. This is without toxicities of the kind associated with chemotherapies. Northwest Biotherapeutics is headquartered in Bethesda, Maryland.
The Company has a wide-ranging platform technology for DCVax dendritic cell-based vaccines. It is working to move ahead with manifold clinical programs, involving DCVax-L and DCVax-Direct. It is pursuing completion of the present Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer and pursuing Phase II combination trials of DCVax-L and checkpoint inhibitor drugs. This includes the Phase II trial of DCVax-L and Pembrolizumab (Keytruda) for colon cancer that was previously announced.
Northwest Biotherapeutics’ lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM) that was on a partial clinical hold in regard to new screening of patients. The Company is underway with a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed enrollment in the Phase I portion of the trial.
Northwest previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania. Also, Northwest Biotherapeutics previously received clearance from the Food and Drug Administration (FDA) for a 612-patient Phase III trial in prostate cancer. It received approval in Germany of a five-year Hospital Exemption for the treatment of all gliomas (primary brain cancers) outside the clinical trial.
This past February, Northwest Biotherapeutics provided a further update regarding its Phase III trial of DCVax®-L for Glioblastoma multiforme (GBM) brain cancer. It announced that the partial clinical hold on the Trial was lifted by the FDA, and that the Trial has accumulated enough events toward the progression-free survival (PFS) endpoint, but not yet for the overall survival (OS) endpoint.
Northwest Biotherapeutics, Inc. (NWBO), closed Monday's trading session at $0.23, up 2.46%, on 325,477 volume with 110 trades. The average volume for the last 60 days is 1,074,059 and the stock's 52-week low/high is $0.221/$0.50.
CD International Enterprises, Inc. (CDII)
The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.025, up 4.34%, on 2,916,056 volume with 134 trades. The stock’s average daily volume over the past 60 days is 734,011 and its 52-week low/high is $0.0001/$48.00.
CD International Enterprises, Inc. a U.S.-based company that sources industrial commodities and provides business and management corporate consulting services, today announces that it has engaged the Corporate Communications Services of QualityStocks. "As a growing international brand, we want to maintain communication with our shareholders while increasing our online visibility and attracting new investors," says Dr. James Wang, chairman and CEO of CD International. "We are excited to work with QualityStocks to achieve these communication goals and look forward to utilizing their expertise in this area."
CD International Enterprises, Inc. (CDII) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
Through its primary website, www.CD International Enterprises, Inc., CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.
At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.
CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.
The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.
Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.
In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer
CD International Enterprises, Inc. Blog
CD International Enterprises, Inc. News:
CD International Enterprises, Inc. (CDII) Announces Engagement of QualityStocks Corporate Communications Suite
CD International Enterprises Enters Agreement to Distribute Cannabidiol (CBD) in the United States
CD International Enterprises Enters Consulting Agreement with Zhangjianjie Shengshi Agricultural Development Company, Limited
India Globalization Capital, Inc. (IGC)
The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.54, up 7.12%, on 426,284 volume with 1,265 trades. The stock’s average daily volume over the past 60 days is 373,342, and its 52-week low/high is $0.19/$0.80.
India Globalization Capital, Inc. announces today that it has filed patent applications for IGC-501 in Canada, Israel, and Europe in support of its global cannabis-based combination therapy development initiatives. IGC-501 is indicated for neuropathic pain. The pain market represents a significant component of the healthcare system and The Journal of Pain in September 2012 reported that the annual estimated national cost of pain ranges from $560 billion to $635 billion. In addition, abuse of prescription opioids is estimated to cost about $25 billion.
India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.
The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.
The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.
IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.
IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.
Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.
Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer
India Globalization Capital, Inc. Company Blog
India Globalization Capital, Inc. News:
IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain
IGC Sells Malaysian Hotel Investment Interest, Consolidates Corporate Focus on Development of Cannabis-Based Combination Therapies
IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders
ProBility Media Corp. (PBYA)
The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.644, up 6.27%, on 11,887 volume with 6 trades. The stock’s average daily volume over the past 60 days is 1,772, and its 52-week low/high is $0.1205/$1.16.
ProBility Media Corp. today announces that it has appointed William (Billy) Smith, Jr., crane and rigging industry veteran, to our newly created vocational advisory board. William ("Billy") Smith, Jr. serves as a Commissioner for the National Commission for the Certification of Crane Operators and also holds the position of Executive Vice President of NBIS Claims and Risk Management which provides crane and rigging insurance. Billy brings more than 30 years of experience in the crane, rigging, and construction industry from labor, management, government, and insurance perspectives. Much of his career has been focused on safety issues and training on safe work practices.
ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.
Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.
Companies currently under the ProBility Media conglomerate include:
- Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
- Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
- 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
- National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.
ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.
The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer
ProBility Media Corp. Company Blog
ProBility Media Corp. News:
ProBility Media Corp. Appoints Billy Smith to the Newly Created Vocational Advisory Board
ProBility Media Corp. Files 10Q, Reports Third Consecutive Quarter of Revenue Growth
ProBility Media Corp. and GlobalSim Inc. Join Forces to Introduce Virtual Reality Training to the Crane Industry
MGX Minerals, Inc. (MGXMF)
The QualityStocks Daily Newsletter would like to spotlight MGX Minerals, Inc. (MGXMF). Today, MGX Minerals, Inc. closed trading at $0.8965, up 2.25%, on 111,284 volume with 67 trades. The stock’s average daily volume over the past 60 days is 146,475, and its 52-week low/high is $0.11/$2.119.
MGX Minerals Inc. MGX Minerals Inc. ("MGX" or the "Company") (CSE: XMG / FKT: 1MG / OTC: MGXMF) is pleased to provide a project development update for its Paradox Basin petrolithium project. The Company has begun unitization of designated oil and gas leases and the staking of overlying mineral claims located contiguous to its Lisbon Valley mineral claims. The purpose of the unitization is to eliminate property boundaries, pool mineral interests and establish the Company's private partner as unit operator. MGX now controls more than 94,000 acres of combined oil and gas leases and mineral claims in the State of Utah. MGX's North American Lithium Brine claims now exceed 1.7M acres.
MGX Minerals, Inc. (MGXMF) a diversified mining company based in Vancouver, holds asset portfolios in lithium, magnesium, and silicon in western Canada, with a stated focus on the development of industrial mineral portfolios in specific commodities and jurisdictions offering near-term production potential, minimal barriers to entry, and low initial capital expenditures. Targeting properties where large-scale development opportunities exist, they prefer to acquire regional control in mineral properties to enhance portfolio value, and engage industry experts to mitigate execution risk and improve time to market.
Positive developments have made the company's lithium operations a special point of interest. An important factor is the company's engineering partner Purlucid Treatment Solutions, which has developed technologies representing a major step in the process of extracting lithium from petroleum brine water (petrolithium). MGX already holds the largest lithium portfolio in Canada, with its Sturgeon Lake property in Alberta and other lithium assets, and the company is the sole proprietary technology holder for processing petrolithium. Purlucid has now successfully demonstrated a way to upgrade brine samples from 67mg/L of lithium to 1600mg/L of lithium, while at the same time removing all magnesium, boron, and potassium. This significant pre-processing achievement, generating solutions 1200 percent higher than anticipated, can be expected to have an impact on the cost of production for the entire petrolithium process, since, according to Purlucid CEO Dr. Preston McEachern, the "biggest challenge in lithium recovery is creating a clean brine."
MGX and Purlucid together are already in the bulk sample and pilot plant design optimization phase of development in preparation for deployment, progressing toward unlocking their calculated 2 million metric ton lithium carbonate resource. The initial petrolithium pilot plant is projected to process 12,000 liters of brine per day, and management now sees a future plant capable of handling over a million liters of brine per day. It can be reasonable that future plants will be located near a major operation's water collection and reinjection sites, complete with available infrastructure already in place. Using a current conservative price of $12,000 per metric ton, and the potential to produce upwards of 14,000 metric tons of lithium carbonate per year, the potential from just one major plant would be revenues of nearly $170 million annually.
Additionally, MGX Minerals holds the sole legal patent on the petrolithium process across North America, and is now planning operations in Utah, near the emerging Gigafactory underway by Tesla, with its anticipated demand for lithium. The company believes there is a virtually endless source of lithium-bearing brines in North America.
Supporting this is the company's operations with silicon and magnesium. MGX Minerals controls three high-grade silicon projects in British Columbia. There are currently no producers of silicon in western North America, and the company is evaluating the economic viability of producing silicon metal from high-purity quartzite. MGX is also now developing North America's next magnesium oxide mine in central British Columbia, a location with good mineralization and excellent infrastructure. Disclaimer
MGX Minerals, Inc. Company Blog
MGX Minerals, Inc. News:
MGX Minerals Announces Unitization of Oil and Gas Leases and Addition of 70,000 Acres Overlying Lithium Brine Claims at Paradox Basin Utah
NetworkNewsWire Announces Publication that Reviews the Global Lithium Market and Discusses Innovators Rising to Meet Demand
MGX Minerals Acquires 110,000 Acres of Paradox Basin, Utah Oil and Gas Leases
ORHub, Inc. (ORHB)
The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.37, up 15.59%, on 198,816 volume with 99 trades. The stock’s average daily volume over the past 60 days is 135,374 and its 52-week low/high is $0.05/$2.09.
ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.
The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.
Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.
Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.
In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.
ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.
The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.
ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.
Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer
ORHub, Inc. Blog
ORHub, Inc. News:
NetworkNewsWire Announces Publication on Solutions for the Health Care Industry's Data Processing Needs
NetworkNewsWire Announces Publication of Discussion on the Value of IT & Big Data Analytics for the Health Care Industry
NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)
Today's Top 3
Small Cap Firm
Promotion Stock Secrets
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Bollente Companies, Inc. (BOLC) Award-Winning Luxury Builder Cullum Homes Makes trutankless® the Exclusive Water Heating Solution in its Communities
- CD International Enterprises, Inc. (CDII) Announces Engagement of QualityStocks Corporate Communications Suite
- ChineseInvestors.com, Inc. (CIIX) to Attend 'Invest 2017' Exhibition in Stuttgart, Germany
- Dominovas Energy Corp. (DNRG) Obtains Partner to Facilitate Financing, Development and Production for RUBICON(TM) Fuel Cell Systems
- eXp World Holdings, Inc. (EXPI) to Present at The MicroCap Conference on April 4th in New York
- GreenStone Healthcare Corp. (GRST) Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
- India Globalization Capital, Inc. (NYSE: IGC) Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain
- InMed Pharmaceuticals Inc. (IMLFF) Unique Approach Featured in Forbes -- CFN Media
- MGX Minerals Inc. (MGXMF) Announces Unitization of Oil and Gas Leases and Addition of 70,000 Acres Overlying Lithium Brine Claims at Paradox Basin Utah
- Monaker Group, Inc. (MKGI) to Present at the 29th Annual ROTH Conference, March 15, 2017
- National Waste Management Holdings, Inc. (NWMH) Expands Territory with Acquisition of Burts Refuse, LLC
- ORHub, Inc. (ORHB) NetworkNewsWire Announces Publication on Solutions for the Health Care Industry's Data Processing Needs
- ProBility Media Corp. (PBYA) Appoints Billy Smith to the Newly Created Vocational Advisory Board
- Players Network (OTCQB: PNTV) CEO Provides 1Q Shareholder Update, Outlook
- Singlepoint, Inc. (SING) NetworkNewsWire Announces Publication Highlighting Several Investment Options in the Marijuana Market
- Stealth Technologies, Inc. (STTH) Announces 5 New Products